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β-site APP cleaving enzyme 1 (BACE1) initiates APP cleavage, which has been reported
to be an inducer of tau pathology by altering proteasome functions in Alzheimer’s
disease (AD). However, the exact relationship between BACE1 and PHF (Paired Helical
Filaments) formation is not clear. In this study, we confirm that BACE1 and Hsc70
are upregulated in the brains of AD patients, and we demonstrate that both proteins
show enhanced expression in lipid rafts from AD-affected triple transgenic mouse brains.
BACE1 targeting increased Hsc70 levels in the membrane and cytoplasm fractions and
downregulated Hsp90 and CHIP in the nucleus in the hippocampi of 3xTg-AD mice.
However, these observations occurred in a proteasome-independent manner in vitro.
The BACE1miR-induced reduction of soluble hyperphosphorylated tau was associated
with a decrease in MAPK activity. However, the BACE1 RNAi-mediated reduction of
hyperphosphorylated tau was only blocked by 3-MA (3-methyladenine) in vitro, and it
resulted in the increase of Hsc70 and LAMP2 in lipid rafts from hippocampi of 3xTg-AD
mice, and upregulation of survival and homeostasis signaling. In summary, our findings
suggest that BACE1 silencing neuroprotects reducing soluble hyperphosphorylated tau,
modulating certain autophagy-related proteins in aged 3xTg-AD mice.
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INTRODUCTION
‘‘Alzheimer’s disease (AD), the most common cause of senile dementia, is characterized by
β-amyloid (βA) plaques, neurofibrillary tangles and extensive neuron loss’’. Although the
pathogenesis of AD is still controversial, one of the most accepted mechanisms is the β-amyloid
hypothesis (Karran et al., 2011; Toyn and Ahlijanian, 2014). BACE1 (β-site APP cleaving
enzyme 1) is a transmembrane aspartic protease that is localized to lipid rafts in human brains
Abbreviations: AD, Alzheimer’s disease; AAV, Adenoassociated viral vectors; BACE1, β-site APP cleaving enzyme 1;
BACE1miR, shRNA miR sequences for silencing BACE1; CMA, chaperone-mediated autophagy; Hsc70, heat shock
protein; CHIP, Hsc70 interacting protein; MAPK, Microtubule associated protein kinase; PHF, paired helicoidal
filaments; 3MA, 3 methyladenine; 3xTg, triple transgenic.
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(Tun et al., 2002; Cordy et al., 2003; Ehehalt et al., 2003) and
is upregulated in AD brains (Fukumoto et al., 2002; Ehehalt
et al., 2003; Yang et al., 2003; Holsinger et al., 2006; Ahmed
et al., 2010). The presence of BACE1 in lipid rafts correlates with
cellular stress (Tamagno et al., 2002, 2005, 2008; Tong et al.,
2005; Vassar et al., 2009; Oda et al., 2010), ceramides (Cordy
et al., 2003; Puglielli et al., 2003; Kalvodova et al., 2005) and
plasma and CNS total cholesterol levels (Refolo et al., 2000, 2001;
Ehehalt et al., 2003; Ghribi et al., 2006; Grimm et al., 2008;
Reed et al., 2014). BACE1-mediated APP processing can occur
in endosomes, endoplasmic reticulum/trans-Golgi network or
the plasma membrane, but it occurs predominantly in lipid
rafts (Riddell et al., 2001; Cordy et al., 2003; Ehehalt et al.,
2003; Kins et al., 2006). APP and BACE1 co-segregation may
be facilited by changes in local membrane environment during
aging, thereby leading to increased β-amyloid production (Cordy
et al., 2003; Kins et al., 2006; Paz Gavilan et al., 2006; Vetrivel and
Thinakaran, 2006).
Because AD is also considered a misfolding pathology,
chaperones play key roles in its etiopathogeny (Balch et al.,
2008; Doyle et al., 2013). Hsc70 (HSP73) is an essential
‘‘housekeeping’’ member of the heat shock protein A (HSPA)
family that is 86% identical to Hsp70 (Hsp72), with which
it shares biochemical and biological characteristics (Kampinga
et al., 2009). Hsc70 mediates co-translational folding, protein
translocation through intracellular membranes, chaperone-
mediated autophagy (CMA), disassembly of clathrin-coated
vesicles, and prevents protein aggregation under stress (Cuervo
and Dice, 2000a; Massey et al., 2006; Bandyopadhyay et al.,
2008). Hsc70 interacts with the Hsc70 interacting protein
(CHIP) carboxy terminus, which functions as an intrinsic
E3 ubiquitin ligase to promote ubiquitination (Jiang et al.,
2001). ‘‘CHIP overexpression increases cellular APP levels and
promotes both APP and phospho-tau ubiquitination’’ (Petrucelli
et al., 2004; Shimura et al., 2004; Kumar et al., 2007). ‘‘In
vitro binding assays have demonstrated direct interactions
between CHIP and both Hsc70 and Hsp70’’ (Ballinger et al.,
1999).
AD patient brains contain significantly higher levels of Hsp70
and Hsc70 (Perez et al., 1991; Lee et al., 2008), and some studies
have described the presence of heat shock proteins in lipid
rafts (Triantafilou et al., 2002; Broquet et al., 2003). Previous
studies have shown that β-amyloid induces tau pathology
through direct alterations of proteasome functions (Oddo et al.,
2008). Recent reports have strongly implicated Hsp70/Hsp90
in tauopathy, because these chaperones regulate stability and
degradation of unfolding protein as, pair helical filaments
(PHF); but its hyperphosphorylation state overload the efficiency
of proteasome-dependent degradation (Bonini, 2002; Sakahira
et al., 2002; Petrucelli et al., 2004; Shimura et al., 2004; Dickey
et al., 2007; Luo et al., 2007; Oddo et al., 2008; Jinwal et al.,
2011). So, when the refolding or degradation of abnormal tau
protein is not executed by the proteasome, autophagy pathways
enter in the scene. Also, depending on the phosphorylation
state of tau can be degraded by the proteasome and by
the autophagy-lysosome system (Ikeda et al., 1998; Murakami
et al., 1998; Oyama et al., 1998; Hamano et al., 2008; Wang
et al., 2009). In this way, autophagy represents a homeostatic
regulatory mechanism to control metabolism and cellular stress-
induced protein aggregation (Singh and Cuervo, 2011), by
macroautophagy or CMA, which faults under neurodegeneration
condition, allowing the hyperphosphorylation of tau and NTFs
formation (Villamil-Ortiz and Cardona-Gomez, 2015).
Therefore, since Hsc70 has been previously linked to
proteasome and CMA, and its dysfunction to tau pathogenesis.
In addition, BACE1 and Hsc70 reside in lipid rafts. Then, in this
study, we have focused in to solve the link between BACE1 and
tau pathogenesis.
EXPERIMENTAL PROCEDURES
Human Brains
Human brains from the Neuroscience Group of Antioquia’s
Neurobank (Universidad de Antioquia) were used. A total
of ten brains from either sex were evaluated, five brains
from patients diagnosed with AD and five control brains
from adult patients without a clinical or family history of
AD or any other neurodegenerative disease. The brains
were optimally preserved by fixing one hemisphere in a
buffered solution of 37% formaldehyde and freezing the
other hemisphere at −80◦C. The inferior temporal gyrus
region was dissected from the frozen hemisphere for
biochemical analysis, and the fixed brains were sectioned
at 1 cm3 and sections of 50 µm were obtained for
histological, immunohistochemical and immunofluorescence
analyses.
Immunohistochemistry
Human brain sections (50 µm) were pre-treated with 10 Mm
Tris, pH 6.0, at 85◦C for 5 min. The slices were treated with
formic acid (20%) for 20min to detect the β-amyloid protein. The
mouse (50 µm coronal sections) and human brain sections were
‘‘treated for 20min in 0.1MPB:methanol (1:1) with 1% hydrogen
peroxide and then incubated for 1 h in 0.1 M PB with 1% BSA
and 0.3% Triton X-100. Slices were then incubated with primary
antibodies, mouse anti-human amyloid beta protein (1:250,
SIGNET) and rabbit anti-BACE1 C-terminal (485–501; 1:100,
Calbiochem), overnight at 4◦C in 0.1 M PB with 0.3% BSA and
0.3% Triton X-100. The slices were incubated with a biotinylated
mouse secondary antibody and then incubated with ABC-HRP
complex (Pierce Biotechnology) for 2 h. Diaminobenzidine
(DAB) was used to develop the staining. The tissues were
dehydrated, covered with mounting solution and observed on an
Eclipse E200 optical microscope (Nikon)’’.
Lipid Raft Isolation
The cerebral cortices and hippocampi were lysed in 1% Triton
lysis buffer (25 mM HEPES, pH 6.5, 150 mM NaCl, 2% TX-100,
1 mM EDTA, and 1 mM PMSF) containing a protease inhibitor
cocktail. An equal volume of 80% sucrose was transferred to
an SW41Ti centrifuge tube and then overlaid with 6.5 ml 30%
sucrose solution and 3.5 ml of 5% sucrose solution containing
25 mM HEPES and 150 mM NaCl at pH 6.5. The discontinuous
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sucrose gradients were ultra-centrifuged for 18 h at 4◦C with an
SW41Ti rotor (Beckman Instruments, Palo Alto, CA, USA) at
200,000 g. The gradient was then fractionated into 12 fractions
from the bottom to the top. Each fraction was then prepared
for Western blotting and confirmed with flotillin and clathrin
antibodies’’.
RNAi Design
We designed shRNA miR sequences for silencing BACE1
(shRNAmiR-BACE1) using the BACE1 RNAi sequences (version
1.3.) previously published by Kao et al. (2004). Following the
same methodologic strategy in Piedrahita et al., 2010, ‘‘these
sequences were cloned into human miR 30-base stem-loops by
polymerase extension of overlapping DNA oligonucleotides.
The following primers were used for polymerase extension to
clone the RNAi into a lentiviral shuttle plasmid (pCMV-GIN-
ZEO.GFP) for transfection in HEK-293T: shBACE1miR forward
primer, 5′-CAGAAGGCTCGAGAAGGTATATGCTGTTGA
CAGTGAGCGCGGACTGCAAGGAGTACAACTATAGTGAA
GCCACAGATGTA-3′, and shBACE1miR reverse primer, 5′-
CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCATGG
ACTGCAAGGAGTACAACTATACATCTGTGGCTTCAC-3′.
The extension products were digested with XhoI and EcoRI
for directional cloning into the pCMV-GIN-ZEO.GFP
vector (Open Biosystem). The following primers were used
for polymerase extension to clone the RNAi vectors for
adeno-associated virus (AAV) production: shBACE1miR
forward primer, 5′-AAAACTCGAGGAGCTCGTGAGCG
CTGGACTGCAAGGAGTACAACTCTGTGAAGCCACAGAT
GGG-3′, and shBACE1miR reverse primer, 5′-
TTTTGGATCCATTAATAGGCAATGGACTGCAAGGAGTA
CAACTCCCATCTGTGGCTTCACAG-3′. These extension
products were digested with XhoI and SpeI for directional
cloning into a U6 expression plasmid that had been digested
with XhoI and XbaI (Boudreau et al., 2009)’’.
Viral Particle Production and Neuron
Culture Transduction
The protocol for producing ‘‘AAV particles for large-scale
production of heterologous proteins used Sf9 insect cell culture
with co-infection of recombinant baculovirus derived from
the Autographa californica nuclear polyhedrosis virus (Urabe
et al., 2002). The shRNAmir-BACE1 expression cassettes were
driven by the mouse U6 promoter and were cloned into
pAAV.CMV.hrGFP, which contained AAV serotype 2/5 inverted
terminal repeats and a CMV-humanized Renilla GFP (hrGFP)-
simian virus 40 poly-(A) reporter cassette (Urabe et al., 2002;
Boudreau et al., 2009). AAV titers were determined using
quantitative PCR and/or DNA slot blot analysis. The AAV
particles were dialyzed before use’’ (Castro-Alvarez et al.,
2014).
Animal Procedures
The animals were housed in the SPF vivarium at the SIU-
Universidad de Antioquia, Medellín, Colombia. ‘‘Animals were
handled according to Colombian animal handling regulations
(Law 84/1989 and resolution 8430/1993) and NIH animal
welfare care guidelines (Public Law 99-158, November 20th,
1985, ‘‘Animals in Research’’)’’. The protocol was approved by
‘‘Ethics committee for animal experimentation’’ from University
of Antioquia (September 29-2011).
Neuronal primary cultures were prepared from 10 pregnant
Wistar rats at E17-E18. Mice from either sex were used, for
a total of 10 C57BL/6 wild-type mice (5–9 months old), 20
18-month-old triple transgenic Alzheimer’s mice (3xTg-AD) that
were treated for 6 months and 30 15-month-old 3xTg-AD mice
that were treated for 3 weeks.
How previously we have described ‘‘The 3xTg-AD mice
(Oddo et al., 2003) and wild-type mice were injected with
2 µL of AAV2/5-BACE1miR or AAV2/5-GFP (control) with
a titer of 1012 genomes per ml into the right hippocampus
(Bregma coordinates: −1.7 antero-posterior, −0.7 lateral and
−1.75 depth). The injections were performed with a 10 ml
Hamilton syringe at a rate of 0.2 µl/min, and 5 min elapsed
after the infusion before the syringe was withdrawn. The
animals were transcardially perfused with 4% paraformaldehyde
in PBS and processed for immunodetection assays. The
brains were cryopreserved with 30% sucrose and stored at
−20◦C. The hippocampi and cerebral cortices were dissected,
immediately frozen, placed on dry ice and stored at −80◦C
until use’’ (Piedrahita et al., 2010; Gutiérrez-Vargas et al.,
2015).
Western Blotting
Human and mouse brain tissue, neuronal primary cultures
and HEK-293T cells were lysed in 150 mM NaCl, 20 mM
Tris, pH 7.4, 10% glycerol, 1 mM EDTA, 1% NP40, 100 µM
phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin and leupeptin
(Sigma), 100 µM orthovanadate (Cardona-Gomez et al.,
2004) and a protease inhibitor cocktail. The proteins (30 µg)
were loaded on 10% SDS-PAGE gels, separated at 110 V
and transferred to nitrocellulose membranes (Amersham)
at 250 mA for 2 h using an electrophoretic transfer system.
The membranes were incubated overnight at 4◦C with rabbit
anti-BACE1 C-terminal (485–501; 1:250, Calbiochem), rabbit
anti-BACE2 (Ab2; 44–59; 1:500, Calbiochem), rabbit anti-
Hsc70 (Hsp73; 1:1000, Assay Designs), mouse anti-Hsp90
(AC88; 1:500, Assay Designs), rabbit anti-CDK5 (C-8; 1:1000,
Santa Cruz Biotechnology), mouse anti-human-PHF-tau
(1:500, Pierce Biotechnology), rabbit anti-phospho-GSK-
3β (Ser9; 1:1000, Cell Signaling Technology), rabbit anti-
phospho-Akt (Ser473; 1:1000, Cell Signaling Technology),
rabbit anti-CHIP (N-terminal; 1:1000, Sigma-Aldrich), rabbit
anti-LC3B (1:500, Cell Signaling Technology), rabbit anti-
LAMP2-A (1:1000, Sigma-Aldrich), mouse anti-flotillin-1
(1:1000, BD Biosciences), rabbit anti-mTOR (1:1000, Cell
Signaling Technology), mouse anti-Bcl-2 (1:500, Santa Cruz
Biotechnology), rabbit anti-HSF1 (1:1000, Cell Signaling
Technology), rabbit anti-phospho-mTOR (Ser2448; 1:1000,
Cell Signaling Technology), rabbit anti-phospho-p70 S6
kinase (Thr389; 1:1000, Cell Signaling Technology), rabbit
anti-beclin-1 (1:1000, Cell Signaling Technology), rabbit
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anti-FoxO3 (1:1000, Cell Signaling Technology), mouse anti-
presenilin-1 (APS 18; 1:250, Pierce Biotechnology), PHF-1
monoclonal antibody, which recognizes TaupSer-396/404
(1:1000) donated by P. Davies (Feinstein Institute for Medical
Research, Manhasset, NY, USA), mouse anti-Phospho-PHF-
tau pSer202/Thr205 Antibody (AT8; 1:1000, Thermo Fisher
Scientific), mouse anti-phospho-PHF-tau pThr212/Ser214
Antibody (AT100; 1:1000, Thermo Fisher Scientific), mouse
anti-phospho-PHF-tau pThr231 Antibody (AT180), (1:1000,
Thermo Fisher Scientific), mouse anti-Tau Antibody (TAU-5;
1:1000, Invitrogen) anti-APP A4 (Millipore, Billerica, MA
1:500), anti-APP C-terminal antibody (Sigma-Aldrich 1.500),
anti-Amyloid β (6E10, signet, Covance 1:1000) and mouse
anti-βIII tubulin (1:1000, Promega Corporation) or mouse
anti-β Actin (1:2000, Sigma-Aldrich) antibodies. The following
secondary antibodies were used: IRDye 800CW goat anti-mouse
or rabbit (LI-COR, Inc., diluted 1:5000) and peroxidase-
conjugated anti-mouse IgG or anti-rabbit IgG (Jackson
Laboratories, diluted 1:10,000) antibodies (Table 1). The
blots were developed using an Odyssey Infrared Imaging
System or chemiluminescence (ECL Western blotting system,
Amersham) followed by exposure to radiographic film (ECL
Hyperfilm, Amersham). The films were analyzed using
ImageJ Software (NIH) and Quantity One, version 4.3.0
(Bio-Rad)’’.
Immunofluorescence Microscopy
‘‘The mouse brains were cut into 50 µm coronal sections
with a vibratome (Leica 1000) and treated with 50 mM
ammonium chloride (NH4Cl) for 10 min at room temperature.
The slices were pre-incubated for 1 h in 1% BSA with 0.3%
Triton X-100 in 0.1 M PB. The primary antibodies were
incubated overnight at 4◦C: rabbit anti-BACE1 C-Terminal
(485–501; 1:250, Calbiochem), rabbit anti-BACE2 (Ab2; 44–59;
1:250, Calbiochem), mouse anti-human-PHF-tau (1:250, Pierce
Biotechnology), and rabbit anti-Hsc70 (Hsp73; 1:250, Assay
Designs). Alexa 488- and 594-conjugated secondary antibodies
(Molecular Probes) were used. The slices were observed by
fluorescence microscopy (Olympus IX81), and the individual
images for GFP, BACE1, BACE2, PHF and Hsc70 expression
were analyzed using Image Scope Pro software (Media
Cybernetics). Deconvolution was performed using Image Scope
Pro software (Media Cybernetics) and Cell Software (Olympus)’’.
Measuring Aβ40 and Aβ42 Levels
‘‘The Aβ40 and Aβ42 protein levels from the hippocampi
of 15-month-old 3xTg-AD mice that had been treated with
AAV2/5-BACE1miR (BACE1miR) or AAV2/5-GFP (GFP) for
one month were measured by ELISA, as described in the
manufacturer’s instructions (BetaMark x-42 ELISA Protocol-
SIG-38956-kit and BetaMark x-40 ELISA Protocol-SIG-38950-
kit)’’.
Soluble and Insoluble Tau Quantification
The hippocampi from 15-month-old 3xTg-AD mice that
had been treated with AAV2/5-BACE1miR (BACE1miR) or
TABLE 1 | Antibodies information.
Antibody Laboratory Dilution
Rabbit–anti-BACE1 C-terminal (485–501) Calbiochem 1:250
Rabbit anti-BACE2 (Ab2; 44–59) Calbiochem 1:500
Rabbit anti-Hsc70 (Hsp73) Assay Designs 1:1000
Mouse anti-Hsp90 (AC88) Assay Designs 1:500
Rabbit anti-CDK5 (C-8) Santa Cruz Biotechnology 1:1000
Mouse anti-human-PHF-tau Pierce Biotechnology 1:500
Mouse anti-presenilin-1 (APS 18) Pierce Biotechnology 1:250
Rabbit anti-phospho-GSK-3β (Ser9) Cell Signaling Technology 1:1000
Rabbit anti-phospho-Akt (Ser473) Cell Signaling Technology 1:1000
Rabbit anti-CHIP (N-terminal) Sigma-Aldrich 1:1000
Rabbit anti-LC3B Cell Signaling Technology 1:500
Rabbit anti-LAMP2-A Sigma-Aldrich 1:1000
Mouse anti-flotillin-1 BD Biosciences 1:1000
Rabbit anti-mTOR Cell Signaling Technology 1:1000
Rabbit anit-phospho-mTOR (Ser2448) Cell Signaling Technology 1:1000
Mouse anti-Bcl-2 Santa Cruz Biotechnology 1:500
Rabbit anti-HSF1 Cell Signaling Technology 1:1000
Rabbit anit-phospho-p70 S6 Cell Signaling Technology 1:1000
kinase (Thr389)
Rabbit anit-p70 S6 kinase Cell Signaling Technology 1:1000
Rabbit anti-beclin-1 Cell Signaling Technology 1:1000
Rabbit anti-FoxO3 Cell Signaling Technology 1:1000
Mouse anti-Phospho-PHF-tau pSer202 + Thermo Fisher Scientific 1:1000
Thr205 Antibody (AT8)
Mouse anti-phospho-PHF-tau pThr212 + Thermo Fisher Scientific 1:1000
Ser214 Antibody (AT100)
Mouse anti-phospho-PHF-tau pThr231 Thermo Fisher Scientific 1:1000
Antibody (AT180)
Mouse anti-Tau Antibody (TAU-5) Thermo Fisher Scientific 1:1000
Rabbit anti-APP A4 Millipore, Billerica, MA 1:500
Rabbit anti-APP C-terminal antibody Sigma-Aldrich 1:500
Mouse anti-Amyloid β (6E10) Signet, covance 1:1000
Mouse anti-βIII tubulin Promega Corporation 1:1000
Mouse anti-β Actin Sigma-Aldrich 1:2000
IRDye 800CW goat anti-mouse or rabbit LI-COR, Inc. 1:5000
Peroxidase-conjugated anti-mouse IgG Jackson Laboratories 1:10,000
Peroxidase-conjugated anti-rabbit IgG Jackson Laboratories 1:10,000
AAV2/5-GFP (GFP) for three weeks were lysed in ‘‘150 mM
NaCl, 20 mM Tris, pH 7.4, 10% glycerol, 1 mM EDTA, 1%
NP40, 100µMphenylmethylsulfonyl fluoride, 1µg/ml aprotinin
and leupeptin (Sigma), 100 µMorthovanadate (Cardona-Gomez
et al., 2004) and a protease inhibitor cocktail. The lysates were
centrifuged at 13,000 rpm at 4◦C for 10 min. A fraction of the
supernatant was stored as the soluble fraction. The remaining
fraction was diluted in sarkosyl buffer (50 mM Tris HCl, pH
7.4; 0.15 M NaCl, 1% lauryl sarcosamine, and protease inhibitor
cocktail) and centrifuged at 13,000 rpm at 4◦C for 10 min. The
supernatant was incubated for 30 min at RT and centrifuged
at 170,000 g for 2 h. The pellet was diluted in sarkosyl buffer
and stored as the insoluble fraction. The soluble and insoluble
fractions were analyzed byWestern blotting, as described above’’.
In Vitro CDK5 Kinase Assay
‘‘Neuronal primary cultures were transduced for 7 days with
AAV2/5-BACE1miR or AAV2/5-GFP (transduction control)
and then placed in 1.5 ml microfuge tubes containing lysis
buffer, rapidly frozen using liquid nitrogen immersion, and kept
frozen until the assay was performed. Then, the sample was
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thawed on ice, homogenized, incubated for 15 min on ice, and
centrifuged at 13,000 rpm at 4◦C. The supernatant was recovered
in clean microfuge tubes, and the protein concentration was
measured with the bicinchonic acid method (Thermo Fisher
Scientific). CDK5 was immunoprecipitated from 250 µg of total
protein using 1 µg of the rabbit polyclonal anti-CDK5 (C-
8) antibody (Santa Cruz). The antibody was incubated with
the protein extract overnight at 4◦C on a rotator. Protein G-
Sepharose (Sigma-Aldrich) was added, and the samples were
incubated for an additional 1 h at 23◦C. The Protein G-Sepharose
beads were washed five times with immunoprecipitation (IP)
buffer (Sigma-Aldrich), while maintaining the sample at 4◦C.
After the fifth wash, the Protein G-Sepharose beads were
resuspended in 200 µl of kinase assay buffer (20 mM Tris-
HCl, pH 7.5, 100 µM sodium orthovanadate, 10 mM MgCl2,
50 mM NaCl, 1 mM DTT, and 1 mM NaF), and ATP was
added to the resuspended beads at a 10-fold excess (0.5 mM).
Histones from calf thymus type III-S (Sigma- Aldrich) were
added at a final concentration of 6 µM as a substrate for
CDK5, and then the reaction was gently vortexed, aliquoted and
incubated at 37◦C for 30 min. To stop the reaction, 5 µl of
SDS-PAGE loading buffer (250 mM Tris-HCl, 10% SDS, 30%
glycerol, 0.5 M DTT, 0.02% bromophenol blue) was added,
and the samples were immediately incubated for 5 min at
95◦C. The samples were separated electrophoretically at 120 V
for 2 h and transferred to a nitrocellulose membrane at 200
mA for 1.5 h. Ponceau Red in 5% acetic acid was used to
stain the transferred proteins. The histones were clearly visible,
and migrated at approximately 21 kDa on the gel. Western
blots for CDK5 (C-8 antibody) and rabbit polyclonal anti-
phosphorylated histone H1 (Millipore; 06-597) were used. Goat
anti-rabbit IRDye 800WE (LI-COR) was used as the secondary
antibody and detected using anOdyssey Infrared Imaging System
(LI-COR). The band intensities for the histones were measured
withNIH ImageJ software and normalized to the IgG heavy chain
intensity’’.
In Vitro MAP Kinase Assay
We used the MAP Kinase/Erk IP Kinase Assay kit (Millipore
# 17-192) according to the manufacturer’s instructions. ‘‘The
assay kit is designed to measure phosphotransferase activity
in an immunocomplex formed between the MAP Kinase R2
antibody and MAP Kinase (p44mpk). This precipitated enzyme
is used to phosphorylate a specific substrate, myelin basic
protein (MBP). The phosphorylated substrate is then analyzed by
Western blotting using an antibody specific for phosphorylated
MBP. The measurement of MAPK activity in most cell lysates
is not accurate due to the phosphorylation of MBP by other
kinases’’.
PP2A Activity Measurement
‘‘PP2A phosphatase activity from the hippocampi of 3xTg-AD
mice (18-month-old) treated for 6 months with AAV2/5-
BACE1miR or AAV2/5-GFP (control), were analyzed with a
PP2A IP Phosphatase Assay Kit (Millipore) as described in the
manufacturer’s instructions’’.
Cellular Fractions
The cerebral cortices and hippocampi from wild-type and
3xTg-AD mice were ‘‘homogenized in 100 mM Tris, pH 7.4,
3 mM MgCl2, 0.32 M sucrose, 0.1% Triton X-100 (Buffer A),
and a protease inhibitor cocktail (Sigma-Aldrich). The soluble
fraction was obtained after centrifuging at 2500 rpm for 15 min
at 4◦C. The pellet was suspended in Buffer A and loaded
on a two-layer sucrose cushion; the first one was Buffer B
containing 1.9 M sucrose and the second, Buffer C, contained
2 M sucrose. The sample was then centrifuged for 1 h at 10,000
rpm at 4◦C. The membrane fraction was at the top of the
2 M sucrose layer, whereas the nuclear fraction was at the
bottom’’.
In Vitro Assays
‘‘Cortical primary cultures (5 × 105 cells/well or 1 × 106
cells/well) from C57BL/6 mice or Wistar rat embryos (E17-E18)
were dissected, trypsinized, dissociated and cultured on
poly-L-lysine-coated (Sigma-Aldrich) 24-well or 6-well plates
respectively, in Neurobasal medium (GIBCO) containing B-27
supplement, (Sigma-Aldrich), and penicillin-streptomycin
(GIBCO), at 37◦C in a 5% CO2 humidified atmosphere. At
DIV5, the neuronal primary cultures in 6-well plates were
transduced with 2 µl of AAV2/5-BACE1miR or AAV2/5-GFP
(transduction control) with 1012 genomes per ml titer for 7
days’’ (Piedrahita et al., 2010). At DIV 12, the neurons were
exposed to lactacystin (synthetic; 10 µM, Calbiochem), KNK437
heat shock protein inhibitor I, (100 µM, Calbiochem), or the
autophagy inhibitors 3-methyladenine (10 mM, Sigma-Aldrich),
bafilomycin (100 nM, Sigma-Aldrich), ammonium chloride
(NH4Cl, 20 mM, Sigma-Aldrich) or DMSO (Sigma-Aldrich)
for 24 h.
Statistical Analysis
‘‘The n used for in vitro and in vivo experiments were
3–6. Parametric data were compared using multi-variable
two-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test for comparisons between several
independent groups. A p < 0.05 confidence level using
a two-tailed test was adopted as statistically significant.
The Student’s t-test was used to compare two groups. The
data were expressed as the means ± SEM. The analyses
were performed with SPSS (IBM) and GraphPad Prism
version 4.00, 2003 (GraphPad Software Inc., San Diego, CA,
USA)’’.
RESULTS
BACE1 and Hsc70 were Upregulated in AD
Brains, and Hsc70 is Retained in Lipid
Rafts
The relationship between BACE1 and Hsc70 was evaluated
in the inferior temporal gyrus of AD-affected human brains.
The typical hallmarks of AD (β-amyloid and PHF-1) were
detected, and BACE1 and Hsc70 immunoreactivity were
increased (Figure 1A). BACE1 and Hsc70 protein levels were
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upregulated, whereas a related protein, the CHIP carboxyl
terminus, remained unchanged compared to the levels in control
brains (Figure 1B).
It is widely accepted that BACE1 is enriched in lipid
rafts in AD (Riddell et al., 2001; Cordy et al., 2003; Ehehalt
et al., 2003). Lipid rafts were isolated from 15-month-old
triple transgenic mouse brains (3xTg-AD) to determine
whether BACE1 and Hsc70 were associated in these micro-
domains. BACE1 and Hsc70 proteins were significantly
increased in isolated lipid rafts (flotillin-positive fractions,
data not shown). CHIP was not changed and Hsp90
and PHF-1 proteins were not detected (Figure 1C).
Interestingly, Hsc70 levels were significantly reduced in the
cytoplasmic fractions from the brains of the 3xTg-AD mice
in comparison with the wild-type mice (Figure 1D). These
data suggest that the additional Hsc70 is retained in lipid
rafts when BACE1 is increased in this micro-domain in AD
brains.
Specific Silencing of BACE 1 Reduces
β-Amyloidosis in the Hippocampus of
3xTg-AD Mice
We generated a recombinant AAV (serotype 2/5), which
expresses BACE1miR in addition to a GFP reporter. We
evaluated the effect of the BACE1 shRNA-miR treatment on
β-amyloidosis in 3xTg-AD mice. Initially, the AAV:BACE1miR
vector was injected into the right hippocampus of 5–9-month-
old wild-type mice to evaluate gene silencing at 3 weeks,
3 months and 6 months post-injection. We observed reduced
BACE1 protein levels in the brains that were injected with
the BACE1miR compared to the GFP control as detected by
Western blotting (Figure 2A) and confocal immunofluorescence
analysis; BACE2 expression was not affected (Figure 2B). In
addition, there was a significant decrease in BACE1 as well as
β-amyloid immunoreactivity in the 3xTg-AD mice at 6 months
after injection with the BACE1miR compared to the GFP-
treated animals (Figure 2C). We also confirmed the reduced
levels of BACE1 by Western blotting. Moreover, the level of the
CTF-β fragment was significantly reduced; however, the levels of
APP-CT, APP-NT, full-length PS1 and C-terminal PS1 proteins
did not change (Figure 2D). BACE1miR specifically reduced
Aβ-42 levels, without changing the Aβ-40 levels (Figure 2E).
Therefore, our findings confirm that the BACE1miR reduced
BACE1 levels and β-amyloidosis, as previously reported (Luo
et al., 2001; Kao et al., 2004; Ohno et al., 2004; Laird et al.,
2005).
BACE1 Targeting Decreases Soluble
Hyperphosphorylated Tau by Reducing
MAP Kinase Activity in the Hippocampus
of 3xTg-AD Mice
Unexpectedly, a significant reduction in the number of PHF-
positive cells was observed in the hippocampus (Figure 3A).
However, only the level of soluble tau was reduced by
BACE1miR, and the level of insoluble tau was even increased
(Figure 3B). In addition, PHF-1 protein levels were reduced by
BACEmiR, whereas the levels of AT-8, AT-100, AT-180 and
TAU-5 were not changed (Figure 3C). To understand the cellular
mechanism of hyperphosphorylated tau reduction, we evaluated
the various kinases involved, as well as protein phosphatase
2A (PP2A) and Bcl-2. The CDK5 protein levels (Figure 3D),
CDK5 activity (Figure 3E), GSK-β, GSK-β (Figure 3F), Bcl-2
(Figure 3G), ERK-1, ERK-2 (Figure 3H) and PP2A activity
(Figure 3I) were not modified in BACE1miR-treated 3xTg-AD
mice. Interestingly, our data showed that MAPK activity was
significantly reduced by BACEmiR (Figure 3H), while Bcl-2 was
upregulated (Figure 3G), suggesting impacts on cell survival.
BACE1 Silencing Upregulated Hsc70 in the
Cytoplasm and Reduced Hsp90 in the
Nucleus
To examine the relationship between BACE1 and Hsc70, Hsc70
protein expression was evaluated in the brains of BACE1miR-
treated 3xTg-AD mice. The brain slices showed a significant
increase in Hsc70 fluorescence intensity in the CA1 area
compared to the GFP control group (Figures 4A,B). The
subcellular localization of Hsc70 is critical for its specific
functions (D’Souza and Brown, 1998; Chen and Brown, 2007).
The localization of Hsc70 and of other related proteins was
determined by cellular fractionation and Western blotting from
the hippocampi of BACE1miR-treated 3xTg-AD mice. Hsc70
was significantly increased in the cytoplasm and membrane
fractions; however, its expression in the nucleus was not changed.
Interestingly, the Hsp90 protein level was decreased in the
cytoplasm and nuclear fractions, but it remained unchanged
in the membrane fraction. Moreover, CHIP was significantly
increased in the cytoplasm and decreased in the nucleus
(Figures 4C–E). Also, HSF-1 was reduced by the BACEmiR
treatment, meaning a non transcriptional upregulation of Hsc 70
(Figure 4F).
BACE1miR Reduced Hyperphosphorylated
Tau in a Proteasome-Independent Manner
In Vitro
As in the in vivo model, using protein extracts from
transduced cultured cortical neurons, we confirmed that
AAV2/5-BACE1miR downregulated BACE1, PHF-1, and Hsp90
and upregulated Hsc 70, while CHIP remained unchanged
(Figure 5A). BACE1miR did not affect the typical enzymes
involved in tau hyperphosphorylation, such as GSK-3 and CDK5;
however, pSer473 Akt showed a modest decrease (Figure 5A).
We used these primary neuronal cultures and the proteasome
inhibitor lactacystin to assess whether PHF clearance by BACE1
silencing was proteasome-dependent.
Neuronal cultures transduced with AAV2/5-BACE1miR
maintained a significant reduction in PHF-1 protein levels
despite treatment with lactacystin (proteasome inhibitor) and
KNK437 (heat shock protein inhibitor; Figure 5B). As expected,
lactacystin increased the levels of Hsp90 and Hsc70, whereas
cells treated with BACE1miR did not show increases in Hsp90
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FIGURE 1 | BACE1 and Hsc70 in AD-affected human brains and in lipid rafts from triple-transgenic Alzheimer’s disease mouse brains. (A) β-amyloid,
PHF-1, BACE1 and Hsc70 immunoreactivity in the temporal gyrus of AD-affected brains (AD) and control brains. 40× magnification; scale bar: 20 µm. n = 4.
(B) BACE1, Hsc70 and CHIP Western blotting from the temporal gyrus of AD brains (AD); normal human brains were used as controls. A representative plot is
shown. βIII-tubulin was used as a loading control. Densitometric quantification was performed; RU = relative units. n = 4, ∗p < 0.05. (C) Western blotting of BACE1,
Hsc70, Hsp90, CHIP and PHF-1 proteins in lipid rafts isolated from the cerebral cortex of 15-month-old wild-type and 3xTg-AD mice. Flotillin-1 was used as a
loading control. Densitometric quantification was performed; RU = relative units. n = 3, ∗p < 0.05. (D) Western blotting of Hsc70 in the cytoplasmic fraction from the
cerebral cortex of wild-type and 3xTg-AD mice. RU = relative units. n = 3, ∗p < 0.05. Representative blots are shown. The arrow shows the band corresponding to
the expected molecular weight of the BACE1 protein.
and Hsc70. KNK437 produced similar effects. CHIP was not
modified by any treatment (Figures 5C–E).
The BACE1miR-Mediated Reduction in
Hyperphosphorylated Tau was Blocked by
3-MA, an Autophagy Inhibitor
In addition to the proteasome pathway, macroautophagy is
another important mechanism that is involved in the unfolded
protein response and is specifically related to aggregated tau
(Ikeda et al., 1998; Murakami et al., 1998; Wang et al., 2006a,
2009; Hamano et al., 2008). Dysfunction of this pathway has
been reported in AD (Cataldo et al., 2004a,b; Yu et al., 2004,
2005; Nixon et al., 2005; Boland et al., 2008). A macroautophagy
marker, LC3B, was evaluated in the in vitro experiment. We
found that LC3B was significantly increased in BACE1miR-
treated neuronal primary cultures, and this increase was not
reversed by lactacystin or KNK437 (Figure 5F). Together,
these data suggest a proteasome-independent mechanism for
hyperphosphorylation tau loss induced by BACE1miR that
involves the up-regulation of LC3B.
Primary neuronal cultures transduced with AAV2/5-
BACE1miR or AAV2/5-GFP were exposed to autophagy
inhibitors, including 3-methyladenine (3-MA, 10 mM,
macroautophagy inhibitor), bafilomycin (100 nM,
autophagolysosome inhibitor), ammonium chloride (NH4Cl,
20 mM, lysosome inhibitor), or DMSO for 24 h to analyze
the involvement of the autophagic pathway in the BACE1
silencing effects on PHF immunoreactivity. As expected,
LC3B-II (autophagosome formation marker) was significantly
upregulated by BACE1miR (Figure 6A). Likewise, 3-MA
(Figure 6B), bafilomycin (Figure 6C) and NH4Cl (Figure 6D)
reversed the effects of BACE1miR on LC3B-II, while LC3B-I
was only decreased by NH4Cl treatment (Figure 6D). However,
the BACE1miR-mediated reduction of PHF-1 protein levels
was blocked only by the inhibitor 3-methyladenine and not by
bafilomycin or ammonium chloride (Figure 6E). Quantification
of the LC3B fluorescence intensity (Figures 6F–N) confirmed
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FIGURE 2 | BACE1miR produces specific BACE1 silencing and reduces β-amyloidosis in 3xTg-AD mice. (A) Representative confocal images of BACE1
and BACE2 immunofluorescence in the hippocampus from wild-type mice at 6 months after injection with AAV2/5-BACE1miR compared to mice with AAV2/5-GFP
injection (Control). Green: GFP fluorescence, red: Alexa 594. 60× magnification; scale bar: 20 µm. n = 3. (B) Representative immunoblots showing BACE1 and
BACE2 protein levels from the hippocampi of wild-type mice at 3 weeks, 3 months and 6 months after injection with AAV2/5-BACE1miR compared to the control
values (AAV2/5-GFP). n = 3. (C) β-secretase 1 (BACE1) and β-amyloid immunoreactivities in the dentate gyrus (DG) of 18-month-old 3xTg-AD mice treated with
AAV2/5-BACE1miR or AAV2/5-GFP as control for 6 months. The black arrowheads show the downregulation of the BACE1 and β-A immunostaining. Green: GFP
fluorescence, adeno-associated virus (AAV) distribution in the DG. 40×, scale bar: 20 µm. n = 3. (D) Representative immunoblots showing BACE1, the C-terminal
fragment (CTF-β), APP-CT, APP-NT, full-length PS1 and the C-terminal fragment of PS1 from the hippocampi of 18-month-old 3xTg-AD mice evaluated at 6 months
after injection of AAV2/5-BACE1miR or AAV2/5-GFP as a control. RU = relative units. n = 4, ∗p < 0.05. (E) β-amyloid 1–40 and 1–42 levels from the hippocampi of
18-month-old 3xTg-AD mice were evaluated by ELISA at 6 months after the injection of AAV2/5-BACE1miR or AAV2/5-GFP; C57BL/6 mice were also used as
controls. Absorbance was measured at 620 nm. n = 5, ∗p < 0.05.
that BACE1miR increased LC3B-II, which was blocked by 3-MA.
Therefore, these results suggest that phosphatidylethanolamine
lipidation is necessary for the BACE1 silencing-induced
dephosphorylation of tau, supported by the increased
LC3B immunoreactivity, but maybe for a non conventional
pathway.
BACE1 Targeting Induces Hsc70/LAMP2
Upregulation in Lipid Rafts from
Hippocampi of 3xTg-AD Mice
The LC3B protein was significantly upregulated in
the cytoplasm and decreased in membrane fractions
(Figure 7A) from the hippocampi of 3xTg-AD mice
treated with BACE1miR compared to the untreated
mice.
Both microautophagy and CMA processing require the
participation of Hsc70/Hsp90, and these proteins were clearly
modified by BACE1miR in a proteasome-independent manner.
Therefore, we evaluated whether LAMP-2A, a CMA-induced
lysosome membrane receptor (Agarraberes et al., 1997; Cuervo
and Dice, 2000a,b; Tanaka et al., 2000; Bampton et al., 2005;
Kaushik et al., 2006; Kiffin et al., 2007; Bandyopadhyay et al.,
2008), was also modulated by BACE1 knockdown in 3xTg-AD
mice. Surprisingly, we found that BACE1miR significantly
increased the levels of LAMP-2A and Hsc70 in lipid rafts
and in the cytoplasmic fraction from 3xTg-AD hippocampi
(Figure 7B).
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FIGURE 3 | BACE1miR reverses hyper-phosphorylated tau in the hippocampus of 3xTg-AD mice. (A) The number of PHF-positive cells in the CA1 region of
the hippocampus of 18-month-old 3xTg-AD mice that were treated with AAV2/5-BACE1miR or AAV2/5-GFP as control for 6 months. The white arrowhead shows a
significant decrease in immunoreactivity. Representative confocal-DSU images ofimmunofluorescence are shown. Red: Alexa 594, 10× magnification, scale bar: 20
µm. n = 3, ∗p < 0.05. (B) Representative bands of the soluble and insoluble fractions of tau. n = 3, ∗p < 0.05. (C) Levels of the hyperphosphorylated tau (PHF-1,
AT8, AT100, AT180 and TAU-5) protein from the hippocampi of 18-month-old 3xTg-AD mice at 6 months after injection with AAV2/5-BACE1miR or AAV2/5-GFP as
control. Representative blots are shown. RU = relative units. n = 4, ∗p < 0.05. (D) CDK5, (E) CDK5 activity, (F) GSK3- β, (G) Bcl-2, (H) MAPK activity and
ERK-1/ERK-2 protein levels were detected. (I) Protein phosphatase 2 (PP2A) activity was quantified using the PP2A Immunoprecipitation (IP) Phosphatase Assay Kit
(Millipore), which detects picomoles of phosphate per microliter. n = 4, ∗p < 0.05. Representative blots are shown. RU = relative units. n = 4, ∗p < 0.05, ∗∗p < 0.001.
BACE 1 Knockdown Induces Survival
Signaling in the Hippocampus of 3xTg-AD
Mice
We evaluated two of the most important mechanisms of
autophagic regulation pathways, Akt/mTOR and Bcl2/Beclin-1
pathways (Figures 8A–D). Although, we did not detect changes
of pSer473 AKT in hippocampi total lysates (Figure 8B),
we detected high protein levels of p2448 mTOR and
increased mTOR activity (Figure 8E) in the hippocampi of
3xTg-AD treated, without changes in pThr389 p70S6K with
BACE1miR compared with the control values, (Figures 8C,D).
Complementarily, the BACEmiR treatment produced increased
protein levels of BCL2 and a reduction of Beclin 1 (Figure 8A),
accompained by an increase of FoXO3, Hsc70, without changes
in total lysates of Hsp90 and CHIP. These findings together,
maybe suggest that the silencing of BACE1 induces survival and
cellular homeostasis.
DISCUSSION
Our data show, for the first time, that BACE1 targeting-induced
protection reduces soluble hyperphosphorylated tau, modulating
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FIGURE 4 | BACE1miR decreases HSF-1, upregulates Hsc70 and induces differential cellular distribution of Hsc70 and Hsp90 in the hippocampus of
3xTg-AD mice. (A) Hippocampi of 18-month-old 3xTg-AD mice at 12 months after injection with AAV2/5-BACE1miR (BACE1miR) or AAV2/5-GFP (GFP).
Immunofluorescence of Hsc70 in the CA1 region of 3xTg-AD mice. The white arrowheads show a significant increase in Hsc70 protein expression in the CA1 region
that was injected with AAV2/5.BACE1miR compared to the left hemisphere (not injected) and to a right hemisphere injected with AAV2/5-GFP (control). Red: Alexa
594. 10X magnification, scale bar: 20 µm. n = 3. (B) Graph of Hsc70 fluorescence intensity (red channel) in the CA1 area showing a significant increase of Hsc70
expression in BACE1miR-treated mice compared to the left hemisphere (not injected) and right hemisphere injected with AAV2/5-GFP (control). Quantification was
performed using image Scope Pro software (Media Cybernetics); RU = relative units. n = 3, ∗p < 0.05. (C) Cellular fractions from the hippocampi of 15-month-old
3xTg-AD mice that were treated with AAV2/5-BACE1miR (BACE1miR) or AAV2/5-GFP (GFP) for three weeks. Hsc70, CHIP and Hsp90 levels in the (C) cytoplasm,
(D) membrane and (E) nuclear fractions. (F) HSF-1 protein expression in the hippocampi of 15-month-old 3xTg-AD mice at three weeks after injection with
AAV2/5-BACE1miR (BACE1miR) or AAV2/5-GFP (GFP). Representative blots are shown. βIII tubulin, flotillin and NeuN were used as loading controls or as fraction
controls. Densitometric quantification was performed; RU = relative units. n = 6, ∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0001.
certain autophagy-related proteins in the hippocampi of aged
3xTg-AD mice.
Cholesterol homeostasis is impaired in AD patients’
brains, thereby enhancing ‘‘β- and γ-secretase activities
and Aβ production in human brains’’ (Xiong et al., 2008).
Cellular cholesterol levels can modulate APP metabolism,
and ‘‘cholesterol depletion reduces the association between
APP and lipid rafts and disrupts the APP–PS1 interaction’’
(Guardia-Laguarta et al., 2009). ‘‘Aberrant cholesterol
trafficking is associated with the potentiation of APP
processing by BACE1, leading to an overall increase in Aβ
levels’’ (Burns et al., 2003). In an APP-overexpressing mouse
model, a cholesterol-rich diet increases Aβ accumulation,
accelerates AD-related pathology (Refolo et al., 2000),
and correlates with tau hyper-phosphorylation (Ghribi
et al., 2006). In the Tg2576 mouse model and in AD-
affected human brains, Aβ dimers appear in lipid rafts
and ApoE progressively accumulates with aging, thereby
facilitating Aβ fibril formation (Kawarabayashi et al.,
2004).
In our study, we found that BACE1 and Hsc70 became
upregulated in human AD brains and increased in lipid rafts
from 3xTg-AD mouse brains. Some studies have described
the presence of heat shock proteins (Hsps) in lipid rafts
(Uittenbogaard et al., 1998; Triantafilou et al., 2002; Broquet
et al., 2003); more recent studies have strongly implicated
molecular chaperones in Aβ and tau pathobiology, particularly
Hsc70, Hsp70, Hsp90 and CHIP (Perez et al., 1991; Cisse
et al., 1993; Dou et al., 2003; Hatakeyama et al., 2004;
Petrucelli et al., 2004; Sahara et al., 2005; Zhang et al., 2005,
2008; Dickey et al., 2006, 2007, 2008; Elliott et al., 2007,
2009; Carrettiero et al., 2009). ‘‘Chaperones are upregulated
not only in cultured neuronal cells overexpressing mutant
forms of APP or treated with synthetic Aβ42 but also in
the cortex and hippocampus of transgenic mice expressing
mutant APP’’. This upregulation is suggested to be a protective
cellular response against Aβ (Hoshino et al., 2007). Aβ
accumulation reduced CHIP levels, and ‘‘Aβ-induced tau
pathology can be rescued by restoring CHIP levels’’ (Oddo et al.,
2008).
BACE1miR was expected to reduce β-amyloidosis (Luo et al.,
2001; Kao et al., 2004; Ohno et al., 2004; Laird et al., 2005) and
also reduce the levels of hyperphosphorylated tau. However,
it did not involve CDK5, GSK3β and PP2A modulation,
but involved MAPK in the reduction of pSer396/pSer404
Tau (PHF-1; Augustinack et al., 2002) and other autophagy
mediators in a non-conventional way. Interestingly, we
found that the BACE1miR induced the translocation of the
chaperone proteins Hsp90 and CHIP, which became drastically
decreased in the nucleus and significantly increased in the
cytoplasm, and Hsc70 was also increased in the membrane
fraction, but maybe in a non transcriptional manner, because
HSF-1 protein levels was reduced (Wang et al., 2006b). The
‘‘Hsp70/CHIP chaperone system plays an important role in
regulating tau turnover and selectively eliminating abnormal
tau species. CHIP interacts directly with Hsp70/90, inducing
ubiquitination of the microtubule-associated protein tau’’
(Petrucelli et al., 2004). The Hsc70-CHIP complex selectively
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FIGURE 5 | BACE1miR decreased hyper-phosphorylated tau in a proteosome-independent manner in primary neuronal cultures. (A) BACE1, PHF-1,
Hsp90, Hsc70, CHIP, pAkt (ser473), GSK3 (pSer9) and CDK5 Western blots from primary neuronal cultures transduced at DIV5 (7 days transduction) with
AAV2/5-BACE1miR or AAV2/5-GFP as a control. Representative blots are shown. Actin was used as a loading control. Densitometric quantification was performed;
RU = relative units. n = 4, ∗p < 0.05, ∗p < 0.001. (B) Western blotting of primary cortical cultures transduced with AAV2/5-BACE1miR or AAV2/5-GFP at DIV5 for 7
days. Neurons were exposed to lactacystin (synthetic; 10 µM), KNK437 heat shock protein inhibitor I, (100 µM) or DMSO for 24 h. Representative blots of (B)
PHF-1, (C) Hsc70, (D) Hsp90, (E) CHIP and (F) LC3-B. βIII-tubulin was used as a loading control. Densitometric quantification was performed; RU = relative units.
n = 4, ∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0001.
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FIGURE 6 | BACE1miR reduces the level of hyperphosphorylated tau, and this effect is blocked by 3-MA. Primary cortical cultures were transduced with
AAV2/5-BACE1miR or AAV2/5-GFP at DIV5 for 7 days. The neurons were exposed to autophagy inhibitors, including 3-methyladenine (10 mM), bafilomycin
(100 nM), ammonium chloride (NH4Cl, 20 mM) or DMSO for 24 h. (A) Representative bands and quantification of the levels of LC-3B I and II proteins from neurons
transduced with AAV2/5-BACE1miR or AAV2/5-GFP and treated with DMSO, (B) 3-methyladenine (10 mM), (C) bafilomycin (100 nM), and (D) ammonium chloride
(NH4Cl, 20 mM). RU = relative units, n = 3, ∗p < 0.05. (E) Representative Western blots for PHF-1 from neurons transduced with AAV2/5-GFP or
AAV2/5-BACE1miR. βIII-tubulin was used as a loading control. Densitometric quantification was performed; RU = relative units. n = 3, ∗p < 0.05. (F,J) GFP
expression in hippocampal neurons transduced with AAV2/5-GFP (control). (H,L) GFP expression in hippocampal neurons transduced with AAV2/5-BACE1miR
(BACE1miR). (G,K) LC3B immunofluorescence in neurons transduced with AAV2/5-GFP (control). (I,M) LC3B immunofluorescence in neurons transduced with
AAV2/5-BACE1miR (BACE1miR). (F–I) Neurons were treated with DMSO as a control; (J–M) neurons were treated with 3-methyladenine (10 mM). Green: GFP
fluorescence, red: Alexa 594 fluorescence. 60X magnification; scale bar: 20 µm. n = 3. (N) Quantification of the LC3B fluorescence intensity using Scope-Pro image
software (Media Cybernetics) in neurons transduced with AAV2/5-BACE1miR or AAV2/5-GFP and treated with 3-methyladenine (10 mM) or DMSO; RU = relative
units, n = 3, ∗p < 0.05.
ubiquitinates phosphorylated tau (Shimura et al., 2004).
CHIP overexpression may antagonize tau accumulation in
AD-affected brains (Zhang et al., 2008). Deleting ‘‘CHIP
results in the accumulation of soluble phospho-tau in the
brain and also sequesters insoluble filamentous aggregates and
prevents cell death’’ (Dickey et al., 2006). Hsp90 inhibitors
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FIGURE 7 | BACE1 silencing upregulates Hsc70 and LAMP-2. Hippocampi of 15-month-old 3xTg-AD mice were analyzed at three weeks after injection with
AAV2/5-BACE1miR (BACE1miR) or AAV2/5-GFP (GFP). (A) LC3-B protein levels in the membrane and cytoplasm fractions. (B) BACE1, Hsc70, and LAMP-2A
protein levels in lipid rafts and LAMP2-A in the cytoplasm from hippocampi of 15-month-old 3xTg-AD mice treated for three weeks with AAV2/5-BACE1miR
(BACE1miR) or AAV2/5-GFP (GFP). βIII tubulin and flotillin were used as a loading control and a fraction control respectively Densitometric quantification was
performed; RU = relative units. n = 4, ∗p < 0.05.
enhance Hsp90/CHIP-mediated phospho-tau degradation
by enhancing endogenous chaperone activity, thereby
‘‘facilitating reductions in phospho-tau accumulation and
selectively targeting the aberrant phospho-tau species associated
with neurotoxicity’’ (Dickey et al., 2007). Elimination of
aggregated tau by Hsp90 inhibition has also been confirmed
in both in vitro and in vivo tauopathy models (Luo et al.,
2007). However, our data suggest that BACE1miR-induced
soluble PHF clearance is proteasome-independent because
proteasome inhibitors did not block the effect of BACE1miR
on hyperphosphorylated tau levels in primary neuronal
cultures.
The ‘‘two major protein degradation systems are the
proteasome pathway and the autophagy-lysosome pathway’’;
damage to lysosomal function is a well-recognized event
in AD neurodegeneration. Lysosome pathology in AD-
affected brains involves changes in macroautophagy
and increased APP proteolysis, and it contributes to Aβ
deposition (Grbovic et al., 2003; Cataldo et al., 2004a,b; Yu
et al., 2004; Nixon et al., 2005; Boland et al., 2008). Our
results suggest that BACE1miR modified some autophagy
mediators because we found that the protein levels of
LC3B and LAMP2 were upregulated. The transcription
of autophagy-related genes, such as LC3B and Bnip3,
occurs during fasting, and Akt/PKB activation blocks
autophagy (Mammucari et al., 2007). Therefore, pSer473
Akt downregulation by BACE1miR could upregulate autophagy-
related genes, thereby increasing LC3B. By contrast, we
found that LC3B was reduced in the membrane fraction of
BACE1miR-treated 3xTg-AD mouse hippocampi. However,
a significant increase in Hsc70/LAMP2 in lipid rafts was
accompanied by a reduction in hyperphosphorylated tau in
vivo, which could suggest some repercussion of BACE1miR
on CMA.
Similarly, two major CMA proteins, Hsc70 and Hsp90,
play critical roles in LAMP-2A complex dynamics on the
lysosome membrane (Bandyopadhyay et al., 2008). LAMP-2 is
a lysosome protein in mammalian cells, and it is necessary for
the fusion of lysosomes with autophagosomes (Tanaka et al.,
2000; Bampton et al., 2005). The ‘‘lysosomal levels of both Hsc70
and LAMP-2A increase when CMA is activated’’ (Agarraberes
et al., 1997; Cuervo and Dice, 2000b). Changes in the dynamic
distribution of LAMP-2A into and out of discrete lysosome
membrane microdomains contribute to the regulation of CMA,
and the number of Hsc70-containing lysosomes increases in
conditions that produce CMA activation (Kaushik et al., 2006).
CMA declines with age because of decreased levels of the
lysosome-associated membrane protein LAMP-2 and decreased
substrate binding to the lysosomes (Cuervo and Dice, 2000a,b;
Massey et al., 2006; Kiffin et al., 2007). Interestingly, our
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FIGURE 8 | Silencing of BACE1 upregulates the survival signaling in 3xTg-AD mice. Survival and quality control regulation pathways were analyzed.
(A) Bcl2/Beclin-1, (B) Akt/FoxO3, (C) Hsc70/Hsp90/CHIP protein levels, (D) mTOR pathway and its activity (E) from the hippocampi of 3xTg-AD mice 24-month-old
after 6 months of injection with AAV2/5-BACE1miR and AAV2/5-GFP version as control. Representative blots are shown. RU = relative unit. n = 4, ∗p < 0.05.
findings showed that Hsc70 and LAMP2-A were increased by
BACE1miR in lipid rafts and in the cytoplasm of 3xTg-ADmouse
brains.
Also, we consistently showed that BACE1miR significantly
reduced both Hsp90 and pSer473 AKT in vitro. It is well
documented that Hsp90 inhibitors (geldanamycin, radicicol,
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and their analogs) dephosphorylate and inactivate Akt (Fujita
et al., 2002), which is associated with both tauopathy and
cancer inhibition (Georgescu, 2010; Jimenez et al., 2011;
Jinwal et al., 2011; Kannaiyan et al., 2011; Chen et al.,
2012). Additionally, downregulation of the HSF-1 transcription
factor could decrease Hsp90 and CHIP in the nucleus (Jolly
et al., 1997; Ali et al., 1998; Bharadwaj et al., 1999; Zhao
et al., 2002; Kim et al., 2005; Wang et al., 2006b) and
downregulate pAkt expression (Fujita et al., 2002; Yun and
Matts, 2005a,b). Moreover, Hsp90 silencing upregulates Bcl-2
protection against 6-OH DA (Alani et al., 2014). Therefore,
it has been suggested that heat shock proteins and autophagy
cooperate for quality control (Dokladny et al., 2015). In
addition, mTOR activity control misfolding protein in metabolic
dyshomeostasis (Qian et al., 2010), how our data suggests in this
study.
On the other hand, our findings correlate with BACE1miR-
induced neuroprotection, which generated a reduction of
sustained tau phosphorylation, and involved heat shock proteins,
phosphatidylethanolamine and MAPK in a similar manner
that to control of cell stress (Dodson et al., 2013) and
cancer inhibition. Phosphatidylethanolamine binding proteins
block MAPK activation and thereby have potential therapeutic
implications in Alzheimer’s disease and cancer (Al-Mulla et al.,
2013; Ling et al., 2014). Additionally, Raf, a component
of the MAPK cascade, interacts with Hsc70 in the mouse
hippocampus in basal conditions (Bonfiglio et al., 2011;
Al-Mulla et al., 2013). However, the exact mechanisms
by which BACE1miR could modulate those targets remain
unknown and require additional studies for understanding the
molecular convergence of these actors and their concomitant
actions.
Finally, autophagy inhibitors reduced the BACE1miR-
induced LC3B levels in vitro, and the BACE1miR-mediated
soluble hyperphosphorylated tau downregulation was only
blocked by 3-MA (a class III PI3K inhibitor), but not by
bafilomycin or NH4Cl in vitro. Together, these data maybe
suggest a role for BACE1miR in the double-membrane
vesicles and in membrane fusion to form autophagosomes,
which requires phosphatidylethanolamine, but they do not
imply a typical autophagic flow because insoluble tau was
not reduced, neither by bafilomycin nor NH4Cl blocked
the reduction of hyperphosphorylated tau. Recently, our
unpublished data show the repercussion of shBACE1miR on
the cellular homeostasis induced by a favorable change of
the fatty acid composition of phospholipids, mainly on LPE
and ePE, by reduction of arachidonic acid (20:4), increase
of DHA (22:6), reduction of cPLA2 activity, reduction of
COX2 levels and improving of the cognitive function after 6
and 12 months post-injection (Villamil-Ortiz and Cardona-
Gomez, 2015). Concomitantly, it could be reflected in the
reduction of proinflammatory signaling as MAPK activity
obtained in this study under the same experimental condition,
which could be to favor of the modulation of CMA and
macroautophagy proteins, and clearance of hyperphosphorylated
tau. Because, MAPK regulates downstream cPLA2 under
lipid peroxidation (Shibata et al., 2011); being the cPLA2
encharged of the formation of derivated plasmanogens
of PE (Makide et al., 2009), and this enzyme activation is
close related to hyperphosphorylated tau, inflammation and
neurodegeneration (Sundaram et al., 2012). Therefore, the
inhibition of PE lipidation of LC3B by 3MA, could be affecting
the action of BACE1 silencing on PE fatty acid composition.
However, future studies must be developed to determine the
specific mechanism of that regulation by BACE1miR. Also,
it has recently been shown that phosphatidylethanolamine
regulates autophagy and longevity (Rockenfeller et al.,
2015), and LC3 lipidation are involved in autophagy and
lipid metabolism turnover (Singh et al., 2009), which could
be related with tissue homeostasis and improvement of
cognitive function of 3xTg-AD mice treated with BACE1miR
during 6 and 12 months (Villamil-Ortiz and Cardona-Gomez,
2015).
In summary, our study has extended the role of BACE1
beyond its role in APP cleavage by linking it to Hsc70
and other mediators of autophagy. BACE1 in lipid rafts is
associated with tau aggregation, but its silencing induces cellular
homeostasis in PE-dependent mode, produce soluble PHF
clearance, involving MAPK inhibition, Hsc70 and LAMP2 in
lipid rafts maybe favoring CMA. These results emphasize that
BACE1 targeting is a promising neuroprotective therapy for
Alzheimer’s disease.
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